International Research Journal of Education and Technology
Peer Reviewed Journal
ISSN 2581-7795

Understanding the Nexus: High Blood Pressure Among Cancer Patients during Treatment

Ramling Basling Mali, Research Scholar, Malwanchal University, Indore

Dr.Berlin Sara Thampy, Research Supervisor, Malwanchal University, Indore

Introduction

Cancer and hypertension, two formidable adversaries of human health, have increasingly been recognized for their interconnectedness. Cancer patients undergoing treatment often face the daunting challenge of managing not only their primary disease but also the emergence or exacerbation of high blood pressure (hypertension). This article delves into the intricate relationship between cancer and hypertension, exploring the underlying mechanisms, prevalence, impact on treatment outcomes, and strategies for effective management.

The Interplay between Cancer and Hypertension

Cancer and hypertension share common risk factors, such as obesity, sedentary lifestyle, and aging. Moreover, certain cancer treatments, including chemotherapy agents and targeted therapies, can directly contribute to the development of hypertension. For instance, vascular endothelial growth factor (VEGF) inhibitors, commonly used in cancer treatment, can disrupt normal vascular function, leading to elevated blood pressure.

Prevalence and Incidence

The prevalence of hypertension among cancer patients varies depending on factors such as cancer type, treatment modalities, and patient demographics. Studies have reported significantly higher rates of hypertension in cancer patients compared to the general population. For instance, research indicates that up to 75% of patients receiving certain targeted therapies develop hypertension during treatment.

Impact on Treatment Outcomes

The presence of hypertension in cancer patients poses significant challenges to treatment outcomes and overall prognosis. Elevated blood pressure can lead to dose reductions or interruptions in cancer therapy, compromising its efficacy. Moreover, hypertension increases

the risk of cardiovascular complications, such as heart failure and stroke, which can further impede cancer treatment and diminish quality of life.

Mechanisms Underlying Hypertension in Cancer Patients

The development of hypertension in cancer patients is multifactorial, involving complex interactions between cancer-related factors, treatment modalities, and patient-specific variables. Several mechanisms contribute to the pathogenesis of hypertension in this population, including:

1. **Endothelial Dysfunction:** Cancer and its treatment can impair endothelial function, leading to vasoconstriction and increased peripheral resistance, thereby elevating blood pressure.
2. **Renin-Angiotensin-Aldosterone System (RAAS) Dysregulation:** Disruption of the RAAS, either by cancer itself or by certain treatments, can result in sodium retention and arterial vasoconstriction, contributing to hypertension.
3. **Sympathetic Nervous System Activation:** Cancer-related stress and treatment-induced toxicity can stimulate sympathetic nervous system activity, leading to heightened vascular tone and blood pressure elevation.
4. **Inflammation and Oxidative Stress:** Chronic inflammation and oxidative stress, hallmark features of cancer, can promote endothelial dysfunction and vascular remodeling, predisposing to hypertension.

Management Strategies

Effective management of hypertension in cancer patients requires a comprehensive, multidisciplinary approach aimed at both blood pressure control and cancer treatment optimization. Key strategies include:

1. **Regular Blood Pressure Monitoring:** Close monitoring of blood pressure throughout cancer treatment is essential for early detection and prompt management of hypertension.
2. **Lifestyle Modifications:** Encouraging lifestyle interventions, such as dietary modifications, weight management, regular exercise, and stress reduction techniques, can help control blood pressure and improve overall cardiovascular health.

3. **Pharmacological Interventions:** Antihypertensive medications, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers, and diuretics, may be prescribed to achieve blood pressure goals while minimizing interference with cancer therapy.
4. **Individualized Treatment Approaches:** Tailoring treatment regimens to individual patient characteristics, including cancer type, stage, comorbidities, and treatment regimen, is essential for optimizing therapeutic efficacy and minimizing adverse effects.
5. **Collaborative Care:** Close collaboration between oncologists, cardiologists, primary care physicians, and other healthcare providers is crucial for integrated management of hypertension and cancer, ensuring comprehensive patient care and optimal treatment outcomes.

Conclusion

The coexistence of cancer and hypertension presents a formidable clinical challenge, requiring a nuanced understanding of the underlying mechanisms, vigilant monitoring, and collaborative management approaches. By addressing hypertension effectively during cancer treatment, healthcare providers can mitigate cardiovascular risk, optimize therapeutic outcomes, and improve the overall quality of life for cancer patients. Continued research efforts aimed at elucidating the complex interplay between cancer and hypertension are essential for advancing our understanding and refining treatment strategies in this vulnerable population.

Reference

1. Gudsoorkar P, Ruf R, Adnani H et al. Onco-hypertension: an emerging specialty. Adv Chronic Kidney Dis 2021;28:477–89.e1. 10.1053/j.ackd.2021.09.011

2. Fraeman KH, Nordstrom BL, Luo W et al. Incidence of new-onset hypertension in cancer patients: a retrospective cohort study. Int J Hypertens 2013;2013:379252. 10.1155/2013/379252 .

3. DCHv D, Dobbin SJH, Neves KB et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circ Res 2021;128:1040–61.

4. Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807–15. 10.1093/annonc/mdn713

5. Kim CS, Han K-D, Choi HS et al. Association of hypertension and blood pressure with kidney cancer risk: a nationwide population-based cohort study. Hypertension 2020;75:1439–46. 10.1161/HYPERTENSIONAHA.120.14820

6. Sanfilippo KM, Mctigue KM, Fidler CJ et al. Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women. Hypertension 2014;63:934–41. 10.1161/HYPERTENSIONAHA.113.02953

7. Stocks T, Van Hemelrijck M, Manjer J et al. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension 2012;59:802–10. 10.1161/HYPERTENSIONAHA.111.189258

8. Gunasekaran PM, Chertow GM, Bhalla V et al. Current status of angiotensin receptor blocker recalls. Hypertension 2019;74:1275–8. 10.1161/HYPERTENSIONAHA.119.13955

9. Camarda N, Travers R, Yang VK et al. VEGF receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications. Curr Oncol Rep 2022;24:463–74. 10.1007/s11912-022-01224-0

10. Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens 2018;12:409–25. 10.1016/j.jash.2018.03.

11. Abdel-Qadir H, Ethier J-L, Lee DS et al. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev 2017;53:120–7. 10.1016/j.ctrv.2016.12.002

12. Pandey AK, Singhi EK, Arroyo JP et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension 2018;71:e1–8. 10.1161/HYPERTENSIONAHA.117.10271

13. Izzedine H, Mangier M, Ory V et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 2014;85:457–70. 10.1038/ki.2013.344

14. van Dorst DCH, Kabadayi S, Oomen-de Hoop E et al. Treatment and implications of vascular endothelial growth factor inhibitor-induced blood pressure rise: a clinical cohort study. J Am Heart Assoc 2023;12:e028050.

15. Cohen JB, Geara AS, Hogan JJ et al. Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management. JACC CardioOncol 2019;1:238–51. 10.1016/j.jaccao.2019.11.009

16. Knijnenburg SL, Jaspers MW, Van Der Pal HJ et al. Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol 2012;7:1416–27. 10.2215/CJN.09620911 .